MediPharm Labs Expands CBN Portfolio with Two New Products

MediPharm Labs Expands CBN Portfolio with Two New Products

  • A leader in CBN products, MediPharm Labs, adds CBN:CBD products to its wellness portfolio for consumers and patients looking for a product without THC effects.
  • New CBN products include CBN:CBD 1:2 Relax Formula Oil and a Northbound high CBN and high CBD vape cartridge.

BARRIE, Ontario — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the expansion of its unique cannabinol (“CBN”) product line.

“Once again MediPharm Labs continues to innovate and commercialize unique cannabinoids. Our exciting new CBN:CBD is a unique formulation that allows consumers a CBN product without the effects of THC. This is an exciting addition to our wellness line of products which is produced to a pharmaceutical quality standard in a GMP licensed facility,” said Bryan Howcroft, CEO, MediPharm Labs. “Remaining on the forefront of innovation, MediPharm continues its pursuit to be recognized as the best precision-based cannabinoid company in the world.”

These new products are the latest being launched after the success of the Company’s CBN:THC Nighttime Formula and Northbound High CBN vape cartridge launched in the second quarter of 2021. CBN is typically found in only trace quantities in the cannabis plant but can be formed through oxidation of THC. Like THC, it binds to the endocannabinoid CB1 receptors but binds 8-10 times less strongly resulting in less psychoactive effects than THC at the same dose.

The Company believes this product addresses an untapped market and is likely to surpass the success of the two current CBN:THC products which, based on October 2021 sales, have an annualized revenue of $1.65M, net of excise duty.

As of today, these new products will be available in Ontario in both retail stores and on the OCS.ca e-commerce website, with plans to distribute to the Company’s other six provincial distributors in the coming months.

The Company looks forward to further communicating new products to improve revenue from Canadian distribution. The Company’s Canadian distribution also acts as proof of concept for international distribution and large pharmaceutical and natural health product contract manufacturing services, given MediPharm Labs’ unique GMP Drug Establishment and Natural Health Product manufacturing licenses.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.

In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing License for the extraction of natural cannabinoids.

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: being recognized as the best precision-based cannabinoid company in the world; addressing an untapped market; surpassing success of previous products; distribution to additional provinces; and Canadian distribution acting as proof of concept for international distribution and large pharmaceutical and natural health product contract manufacturing services. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.


  • Struggle between large, small growers over Ohio cannabis reform
    A Senate measure that would expand significantly the state’s medical marijuana system for businesses and patients got its second committee hearing Tuesday. The proposal is beginning to move as a different and more expansive recreational measure gathers signatures for next year’s ballot.
  • Reps. Dave Joyce and Alexandria Ocasio-Cortez Introduce Legislation To Expunge Marijuana Records
    Today, Representatives Dave Joyce (R-OH) and Alexandria Ocasio-Cortez (D-NY) introduced legislation to incentivize state and local governments to expunge the criminal records of tens of millions of Americans who have previously been convicted of marijuana offenses.
  • New Jersey Entrepreneurs bring social equity company REEForm to East Coast
    Social justice in cannabis is a popular topic, but actual change is elusive. Two New Jersey cannabis entrepreneurs built a business around making a difference in their community. They’re trying to deliver on the promise of social equity in cannabis. On September 14, New Jerseyians gathered at the Doubletree Hilton in Newark to learn about…
  • Head of NORML optimistic on cannabis banking through NDAA
    While defense bills don’t usually interest cannabis advocates, an amendment added by Representative Ed Perlmutter (D-CO) included the language of the SAFE Banking Act in the NDAA. With the standalone bill stalled in the Senate Banking Committee, an amendment to the “must-pass” legislation could be the key.
  • Advocate responds to SD high court overturning adult-use cannabis
    South Dakota’s highest court sided with the state’s governor today in declaring an amendment legalizing cannabis invalid. Amendment A, which passed with 54% support, would have legalized cannabis for anyone over 21.
  • Organizer says next steps on Ohio adult-use cannabis by month’s end
    Ohio attorney Thomas Haren, a representative of the “Coalition to Regulate Marijuana Like Alcohol,” said he expects that enough signatures will be gathered to move a proposal forward that would allow for adult use, sale, and possession of marijuana in Ohio.
  • Montana regulators will reverse proposed CBD, dispensary worker rules
    The Montana Department of Revenue told lawmakers this week that it will strike a pair of proposed rules implementing the state’s fledgling recreational marijuana program after hearing considerable input from members of the public, the cannabis industry and legislators who warned that the rules veered from the intent of House Bill 701, an act passed this session regulating the adult-use pot.
  • Cannabis prices soar in Louisiana due to regulatory bottleneck
    A regulatory bottleneck in Louisiana’s medical marijuana supply chain has inflated costs far beyond the prices found in other states, according to industry experts who testified at the Louisiana Legislature’s Medical Marijuana Commission meeting Thursday.
  • Critics say AZ ‘social equity’ program makes Big Cannabis even richer
    “This is a program that, as currently written, is designed to fail,” attorney Julie Gunnigle said to Arizona Mirror. Gunnigle up until recently worked for Arizona’s Chapter of NORML, an organization that pushes for the reform of marijuana laws across the United States.
  • Bipartisan bill to reduce Wisconsin cannabis fines introduced
    Wisconsin legislators are taking another crack at a bipartisan push to achieve cannabis reform in the state. A new piece of legislation, co-authored by Rep. Shae Sortwell (R-Gibson), Rep. Sylvia Ortiz-Valez (D-Milwaukee), Sen. Lena Taylor (D-Milwaukee) and Sen. Kathleen Bernier (R- Chippewa Falls), reduces existing penalties for cannabis possession.